Concomitant use of carbamazepine and olanzapine and the effect on some behavioral functions in rats

Pharmacological Reports

Volumn 63, Issue 2, 2011, Pages 372-380

  Nowakowska, Elzbieta ^a   Kus, Krzysztof ^a   Polański, Adam ^a   Burda, Kinga ^a   Nowakowska, Anna ^a   Sadowski, Czesław ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antidepressant activity; Carbamazepine; Concomitant use; Memory function; Motor coordination; Olanzapine; Rats

Indexed keywords

CARBAMAZEPINE; OLANZAPINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BIPOLAR DISORDER; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; IMMOBILIZATION; INFORMATION RETRIEVAL; LEARNING ALGORITHM; LOCOMOTION; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOTOR COORDINATION; NONHUMAN; RAT; SEDATION; SINGLE DRUG DOSE; SPATIAL MEMORY; TASK PERFORMANCE; TREATMENT DURATION;

EID: 79955933903     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70503-5     Document Type: Article

References (54)

1. Aldenkamp AP, Alpherrts WC, Moerland MC, Ottevanger N, Van Parys JA: Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia, 1987, 29-36.
2. Aoki M, Tsuji M, Takeda H, Harada Y, Nohara J, Matsumiya T, Chiba H: Antidepressants enhance the antinociceptive effects of carbamazepine in the acetic acid-induced writhing test in mice. Eur J Pharmacol, 2006, 550, 78-83. (Pubitemid 44574498)
3. Austin MP, Mitchel P, Wilhelm K, Parker G, Hickie I, Brodaty H, Chan J et al.: Cognitive function in depression: a distinct pattern of frontal impairment in melancholia? Psychol Med, 1999, 29, 73-85.
4. Barros HM, Leite JR: The effects of carbamazepine on two animal models of depression. Psychopharmacology (Berl), 1987, 92, 340-342. (Pubitemid 17100483)
5. Borkowska A, Rybakowski J: Affects of moclobemide on cognitive functions in depression (Polish). In: Moclobemide - Atypical Inhibitor of Monoaminooxidase - (RIMA). Ed. Rybakowski J, Rzewulska M, Członkowski A, Alfa Media Press, Lublin, 2000, 97-104.
6. Borkowska A, Rybakowski J: Neuroleptic treatment effects on the neurocognitive functions in patients with schizophrenia (Polish). Farmakoter Psychiatr Neurol, 1998, 4, 51-64.
7. Borowicz KK, Stȩpień K, Czuczwar SJ: Fluoxetine enhanced in anticonvulsant effects of conventional antiepileptic drugs in maximal electroshock seizures in mice. Pharmacol Rep, 2006, 58, 83-90.
8. Ciapparelli A, Dell'Osso L, Bandettini di Pogio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC et al.: Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry, 2003, 63, 451-458. (Pubitemid 36547291)
9. 9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32, 499-506.
10. Essman WG: Some neurochemical correlates of altered memory consolidation. Trans NY Acad Sci, 1970, 32, 948-973.
11. Franke P, Maier W, Hardt J, Freiboes R, Litchtermann D, Hain C: Assessment of frontal lobe functioning in schizophrenia an unipolar major depression. Psychopathology, 1993, 26, 76-84. (Pubitemid 23194013)
12. Freeman MP, Stoll AL: Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry, 1998, 155, 12-21.
13. Gawrońska-Szklarz B: Carbamazepine (Polish). In: Monitoring Therapy. Ed. Adamska-Dyniewska H, Publishing House TTM, Łó dź, 1994, 185-193.
14. Graczyk M, Adamczyk A: Carbamazepine in palliative medicine (Polish). Pol Med Paliat, 2005, 4, 88-90.
15. Hawkins CA, Mellanby J, Brown J: Antiepileptic and antiamnesic effect of carbamazepine in experimental limbic epilepsy. J Neurol Neurosurg Psychiatry, 1985, 48, 459-468. (Pubitemid 15064888)
16. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzales FJ, Levy RH: Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 an 10,11-epoxide formation. Biochem Pharmacol, 1994, 47, 1969-1979.
17. Kwamie Y, Persad E, Stancer H: The use of carbamazepine as an adjunctive medication in the treatment of affective disorders: a clinical report. Can J Psychiatry, 1984, 29, 605-608. (Pubitemid 15222985)
18. Lucas RA, Gilfillan DJ, Bergstrom RF: A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol, 1998, 54, 639-643. (Pubitemid 28531426)
19. Magdalan J, Kochman K: Intoxications with carbamazepine - data of the acute intoxication unit in Wroclaw. Adv Clin Exp Med, 2004, 13, 987-991. (Pubitemid 40125116)
20. Meltzer HY: Multi receptor atypical antipsychotic drugs. In: Atypical Antipsychotics. Ed. Ellenbroek BA, Cools AR, Birkhauser Verlag, Basel, 2000, 292-213.
21. Morris R: Development of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods, 1984, 11, 47-60.
22. Nichol MB, Stimmel GL, Lange SC: Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry, 1995, 56, 60-66.
23. Nowakowska E, Bobkiewicz-Kozłowska T: The influence of new antidepressants drugs on cognitive functions (Polish). In: Advences in Pharmacotherapy - the New Antidepressants Drugs. Ed. Nowakowska E, University of Medical Sciences in Poznań, Poznań, 2003, 23-42.
24. Nowakowska E, Chodera A, Kus K: Influence of olanzapina on cognitive functions and catalepsy in rats after single and chronic administration. Pol J Pharmacol, 1999, 51, 295-300. (Pubitemid 29415643)
25. Nowakowska E, Kokot Z: Drug effects on cognitive function (Polish). In: Advances in the Treatment of Afective Disorders. Ed. Nowakowska E, Poznań University of Medical Science, Poznań, 2008, 66-88.
26. Nowakowska E, Kus K, Czubak A, Głowacka D, Matschay A: Some bahavioural effects of carbamazepine - comparison with haloperidol. J Physiol Pharmacol, 2007, 58, 253-264. (Pubitemid 47026560)
27. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol, 1978, 47, 379-391.
28. Pulliainen V, Jokelainen M: Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two year follow up. Epilepsia, 1995, 36, 1195-1202.
29. Rall TW, Schleifer LS: Drugs effective in the therapy of the epilepsies. In: The Pharmacological Basis of Therapeutics. Ed. Gilman AG, Rall TW, Neis AS, Taylor P, Pergamon Press, New York, 1991, 449.
30. Randolph CH, Goldberg TE, Weinberger DR: The neuropsychology of schizophrenia. In: Clinical Neuropsychology. Ed. Heilmann K, Valenstein E, Oxford University Press, Oxford, 1993, 499-521.
31. Rogóż Z: Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice. Pharmacol Rep, 2010, 62, 1191-1196.
32. Rosse RB, Malthora AK, Kim SY, Deusth SI: Visual fixation deficits and evidence of cognitive impairment in schizophrenia. Biol Psychiatry, 1992, 31, 412-414.
33. Rybakowski J: Long-term pharmacological treatment of bipolar disorders. Neuro Endocrinol Lett, 2007, 28 [E-pub].
34. Rybakowski J: Mood-stabilizing drugs in various types of bipolar affective illness (Polish). Psychiatria, 2007, 4, 1-7.
35. Rybakowski J: Recent advances in pharmacological treatment of psychiatric disorders (Polish). Przew Lek, 2007, 2, 224-231.
36. Rybakowski J: Standards for therapy of bipolar affective disorders (Polish). Wiad Psychiatr, 2004, 4, 279-284.
37. Seager MA, Barth VN, Phebus LA, Rasmussen K: Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology, 2005, 181, 126-133. (Pubitemid 41440923)
38. Serretti A, De RD, Lorenzi C, Berardi D: New antipsychotic and schizophrenia: a review on efficacy and side effects. Curr Med Chem, 2004, 11, 343-358. (Pubitemid 38240211)
39. Singh D, Asad M. Effect of soybean administration on the pharmacokinetics of carbamazepine and omeprazole in rats. Fundam Clin Pharmacol, 2009, 24, 351-355.
40. Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P: Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol, 2002, 12, 255-260. (Pubitemid 34462218)
41. Sudha S, Lakshmana MK, Pradhan N: Changes in learning and memory acetylcholinesterase activity and monoamines in brain after chronic carbamazepine administration in rats. Epilepsia, 1995, 36, 416-422.
42. Thompson PJ: Antiepileptic drugs and memory. Epilepsia, 1992, 33, 37-40.
43. Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinalan T, Osuntokun O, Wang WV et al.: Olanzapine plus carbamazepine vs. carbamazepine alone in treating maniac episodes. Br J Psychiatry, 2008, 192, 135-143. (Pubitemid 351269648)
44. Tohen M, Changappa R, Suppes T, Zarate CA, Calabrese JR, Bowden CL, Sachs GS et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patient partially non-responsive to valproate or lithium monotherapy. Arch Gen Psychiatry, 2002, 59, 62-69. (Pubitemid 34044408)
45. Tohen M, Suppes T, Baker RW, Evans AR, Calabrese JR: Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: an 18 month study. Eur Neuropsychopharmacol, 2002, 12, 307.
46. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry, 1997, 58, 295-211.
47. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CM Jr, Tollefson GD et al.: Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol, 1997, 11, 407-418. (Pubitemid 27414397)
48. Trimble MR: Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia, 1987, 28, 37-45.
49. Twycross R, Wilcox A, Charlesworth S, Dickman A (Eds.): Palliative care formulary. 2nd edn., Radcliffe Medical Press, 2002, 120-336.
50. Woodward ND, Purdon SE, Meltzer HY, Zald DH: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine and risperidone in schizophrenia. Int J Neuropsychopharmacol, 2005, 8, 457-472. (Pubitemid 41002500)
51. Wrońska A: Contemporary outlooks on the processes of memory and attentions in schizophrenic patients (Polish). Farmakoter Psychiatr Neurol, 1998, 4, 42-50.
52. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW: A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry, 2002, 63, 1148-1155. (Pubitemid 36084060)
53. Zhang ZJ, Kang WH, Tan QR, Li Q, Gao CG, Zhang FG, Wang HH et al.: Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind randomized, placebo-controlled study. J Psychiatr Res, 2007, 41, 360-369. (Pubitemid 44854983)
54. Zhang ZJ, Tan QR, Tong Q, Li Q, Kang WH, Zhen XC, Post RM: The effectiveness of carbamazepine in unipolar depression: a double-blind randomized, placebo-controlled study. J Affect Disord, 2008, 109, 91-97.